Archive
2022, Volume 8
2021, Volume 7
2020, Volume 6
2019, Volume 5
2018, Volume 4
2017, Volume 3
2016, Volume 2
2015, Volume 1
Special Issues
Cistus × Incanus L. Pandalis Is Highly Effective Against Delta Variant of SARS-CoV-2 in Vitro
Journal of Diseases and Medicinal Plants
Volume 7, Issue 3, September 2021, Pages: 82-86
Received: Aug. 23, 2021; Accepted: Sep. 3, 2021; Published: Sep. 8, 2021
Volume 7, Issue 3, September 2021, Pages: 82-86
Received: Aug. 23, 2021; Accepted: Sep. 3, 2021; Published: Sep. 8, 2021
Views Downloads
Author
Jens-Martin Traeder, Institute of General Medicine, University of Luebeck, Lubeck, Germany
Abstract
Background: Recent studies have shown that a special extract from Cistus x incanus L. Pandalis (Cystus Pandalis® extract) has proven to be effective against SARS-CoV-2 in vitro and it is likely that the extract shows to be effective against other new variants of SARS-CoV-2 like the “Indian” Delta-Variety as well. Methods: In order to verify our claim, we examined how the extract Cystus Pandalis® inhibits the cytopathic action (CPE) of the Coronavirus in a cell model with human intestinal cells (Caco-2). We incubated viruses with the extract and mixed them with the cell cultures. Result: Cystus Pandalis® extract has almost completely inhibited virus growth at concentrations greater than 100 μg/ml. The calculated IC50 (mean inhibitory concentration) for the "Indian" Delta variant was 101 µg/ml. Conclusion: Cistus x incanus L. Pandalis extract (Cystus Pandalis® extract) is capable of preventing cell cultures from being infected by SARS-CoV-2 in-vitro. Because of its high in-vitro potency against the new variants of SARS-CoV-2, it is more than ever reasonable to use Cystus Pandalis® prophylactically in order to decrease the virus load. The development of resistance to the extract is not likely. People tolerate the extract very well. No significant side effects have been detected. Phytopharmaceuticals extraxted from Cistus x incanus L. Pandalis are able to combat viral infections and can help contain future pandamics by being handed in advance profilactically.
Keywords
Cystus Pandalis®, Virus Infection, SARS-CoV-2, Variants, Cistus Incanus, Delta
To cite this article
Jens-Martin Traeder, Cistus × Incanus L. Pandalis Is Highly Effective Against Delta Variant of SARS-CoV-2 in Vitro, Journal of Diseases and Medicinal Plants.
Volume 7, Issue 3, September 2021 , pp. 82-86.
doi: 10.11648/j.jdmp.20210703.13
Copyright
Copyright © 2021 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
DAZ: Mutanten und Virusevolution - Kann Impfen Resistenzen f?rdern? 31.03.2021 https://www.deutsche-apotheker-zeitung.de/news/artikel/2021/03/31/kann-impfen-resistenzen-foerdern/chapter:1.
[2]
Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R.: Viral mutation rates. J Virol. 2010 Oct; 84 (19): 9733-48. doi: 10.1128/JVI.00694-10. Epub 2010 Jul 21.
[3]
Jo, W. K., Drosten, C., & Drexler, J.: The evolutionary dynamics of endemic human coronaviruses, Virus Evolution, Volume 7, Issue 1, January 2021, https://doi.org/10.1093/ve/veab020.
[4]
Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, et al.: Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens. PLOS Biology 13 (7): e1002198. https://doi.org/10.1371/journal.pbio.1002198 (2015).
[5]
Pott R: Polymorphismus bei Cistrosen: Welche Variet?t ist als Heilmittel tauglich? KFN-Pressekonferenz, Vortrag, 8. 11. 2006.
[6]
Petereit F.: Polyphenolische Inhaltsstoffe und Untersuchungen zur entzündungshemmenden Aktivit?t der traditionellen Arzneipflanze Cistus incanus L. (Cistaceae). Dissertation, Universit?t Münster, 1992.
[7]
Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, et al.: A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral research 2007, 76 (1), 38-47. doi: 10.1016/j.antiviral.2007.05.002.
[8]
Rebensburg S, Helfer M, Schneider M, Koppensteiner H, Eberle J, et al.: Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins. Scientific reports 2016, 6, 20394. doi: 10.1038/srep20394.
[9]
Traeder JM: Antivirale Eigenschaften des Extrakts aus Cistus×incanus L. Pandalis auch bei SARS-CoV-2 in vitro nachgewiesen. Zeitschrift für Phytotherapie 2021; 42 (03): 121-126, DOI: 10.1055/a-1302-6097.
[10]
Traeder JM: Extract from Cistus × Incanus L. Pandalis also Effective against “British” Alpha (B. 1.1.7) and “South African” Beta (B. 1.351) SARS-CoV-2 Variants, Journal of Diseases and Medicinal Plants. Vol. 7, No. 2, 2021, pp. 44-47. doi: 10.11648/j.jdmp.20210702.13.
[11]
Mhatre S, Srivastava T, Naik S, Patravale V.: Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review [published online ahead of print, 2020 Jul 17]. Phytomedicine. 2020; 153286.
[12]
Riehle P: Phenolische Inhaltsstoffe in C. incanus Tee – Charakterisierung und Stabilit?t innerhalb der Teezubereitung. Dissertation Universit?t Hamburg (2014).
[13]
Kalus U, Grigorov A, Kadecki O, Jansen JP, Kiesewetter H, et al.: Cistus incanus (CYSTUS052) for treating patients with infection of the upper respiratory tract: a prospective, randomised, placebo-controlled clinical study. Antiviral research 2009, 84 (3), 267-271. doi: 10.1016/j.antiviral.2009.10.001.
[14]
Kalus U, Kiesewetter H, Radtke H.: Effect of CYSTUS052 and green tea on subjective symptoms in patients with infection of the upper respiratory tract. Phytother Res. 2010 Jan; 24 (1): 96-100. doi: 10.1002/ptr.2876. PMID: 19444821.
[15]
Traeder JM: Zistrosenextrakt zur Prophylaxe. Erfahrungsheilkunde 2021; 70: 204-208. Thieme, Stuttgart.
PUBLICATION SERVICES
JOIN US
SPECIAL SERVICES
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186
FOLLOW SciencePG
